CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
The Phase III Team Award for Intergroup-Led Trials was presented to the ME15 Team at Odette Cancer Centre (Sunnybrook Health Sciences Centre) at the CCTG Spring Meeting this weekend. The team members include, Dr. Frances Wright (QI), Roxana Marmolejo, Christina Siwak.
"We are absolutely thrilled to be the recipients of this CCTG Phase III Team Award. We have a fantastic team who work extremely hard to provide our patients with the option of participating in this potentially practice-changing trial, MelMart, the melanoma margins trial."
CCTG is honoured to recognize Dr. Hira Mian with the Ralph Meyer Phase III Program Young Investigator Award which is presented to a young investigator who worked on a Phase III trial and contributed significantly to the conduct the trial.
“I am thrilled to receive this young investigator award which is really on behalf of all my colleagues both at McMaster, CCTG and throughout Canada. Thank you team and looking forward to the many years of collaboration.”
During the Awards Ceremony at the CCTG Annual Spring meeting Dr. Lillian Siu was presented the Dr Joseph Pater Founder's Award for excellence in clinical trials research. The award is for recognizing a network clinical trials research investigator whose leadership and body of work has contributed to significant advances in the understanding, diagnosis, treatment, cure, and prevention of cancer.
Congratulations to the IND241 trial team at Princess Margaret Cancer Centre who were awarded the CCTG IND Team Award at the Annual Spring Meeting this past weekend. The team members include, David Cescon (QI), Julia Wang, Soha Ahrari, Irene Li, Simi Malhotra, Lindsay Muyot, Helia Purnaghshband, Carolina Sanabria Salas, Maria Ye, Divyalakshmi Babu, Jennifer Bornstein, Christine Cater, Julia D'Souza, Shirley Ho, Ansu Jomy Jose, Sul Hee Kim, Irum Mahmood, Alexis Maneja, Karla Moreira, Sam (sang pil) Park, and Rosa Pezzulli
CCTG presented Dr. Erica Tsang from Princess Margaret Cancer Centre the Dr. Elizabeth Eisenhauer Early Drug Development Young Investigator Award to recognize her work as a new investigator who has worked on IND projects and contributed significantly to the conduct of an IND trial at a member centre.
The MA40 trial, a double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER-2 negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor has closed to further accrual as the accrual target of 250 study participants enrolled.
Please join the Patient Representative Committee in welcoming Michelle Audoin who will be supporting the Breast Disease Site committee.
